doxorubicin hydrochloride/teva 2mg/ml c/s.sol.in
teva pharma b.v., utrecht, the netherlands - doxorubicin - ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ - 2mg/ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
adriblastina ps.inj.sol 10mg/vial
pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - doxorubicin hydrochloride - ps.inj.sol (ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 10mg/vial - doxorubicin hydrochloride 10mg - doxorubicin
adriblastina pd.inj.sol 50mg/vial
pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - doxorubicin hydrochloride - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 50mg/vial - doxorubicin hydrochloride 50mg - doxorubicin
adriblastina inj.sol 10mg/5ml vial
pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - doxorubicin hydrochloride - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 10mg/5ml vial - doxorubicin hydrochloride 2mg - doxorubicin
adriblastina inj.sol 50mg/25ml vial
pfizer ΕΛΛΑΣ Α.Ε. Μεσογείων 243,, 154 51 154 51, Νέο Ψυχικό 210.6785800 - doxorubicin hydrochloride - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 50mg/25ml vial - doxorubicin hydrochloride 2mg - doxorubicin
rubidox pd.inj.sol 10mg/vial
medicus a.e. Βαλαωρίτου 10,, 144 52 144 52, Μεταμόρφωση Αττικής 28 15 353, 28 43 479 - doxorubicin hydrochloride - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 10mg/vial - doxorubicin hydrochloride 10mg - doxorubicin
rubidox pd.inj.sol 50mg/vial
medicus a.e. Βαλαωρίτου 10,, 144 52 144 52, Μεταμόρφωση Αττικής 28 15 353, 28 43 479 - doxorubicin hydrochloride - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 50mg/vial - doxorubicin hydrochloride 50mg - doxorubicin
adriblastina 2mg/ml solution for injection
pfizer hellas ae (0000003442) 243 messoghion avenue, neo psychiko, athens, 15451 - doxorubicin hydrochloride - solution for injection - 2mg/ml - doxorubicin hydrochloride (0025316409) 2mg - doxorubicin
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
ambisome 50mg/vial powder for concentr.for liposomal dispers.for inf.
gilead sciences ireland uc (0000009744) ida business & technology park, county cork, carrigtohill, t45 dp77 - amphotericin b - powder for concentr.for liposomal dispers.for inf. - 50mg/vial - amphotericin b (0001397893) 50mg - amphotericin